Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spherix has reported that the Phase III clinical trial of its potential type 2 diabetes drug, Naturlose, will expand outside of the US.
Subscribe to our email newsletter
The company has also announced that it has successfully petitioned the FDA to eliminate the need for pre-mixed solutions for the delivery of study medicine to participants.
Randy Brown, chief of operations at Spherix, said: “This expansion abroad should allow us to finish enrollment in the first quarter of 2009, which is consistent with the timeline reported at the recent shareholders meeting.”